(Adnkronos) - Il progetto “Cambiamo rotta” patrocinato da Acto Italia, Alleanza contro il Tumore Ovarico, e sponsorizzato da Gsk ha fatto tappa in Campania e ora anche in Veneto, a Treviso, con il patrocinio di Acto Triveneto. L’incontro ha coinvolto esperti della ginecologia oncologica del Triveneto e le istituzioni politico-sanitarie in un confronto sui percorsi di cura e prevenzione del tumore ovarico, dedicato alle donne colpite dalla malattia e ai i loro familiari.
Category
🗞
NewsTranscript
00:00There are about 6,000 new diagnoses of ovarian cancer every year in Italy.
00:08Compared to the past, we live more and we would like to live better.
00:12Acto Italia, an alliance against ovarian cancer, has sponsored the Cambiamo Rotta project,
00:17the first white book illustrated in the voice of the needs and proposals of women affected by this neoplasia.
00:22Presented before the Ministry of Health, Cambiamo Rotta has made a breakthrough in Campania and now also in Veneto,
00:28with the sponsorship of Acto Triveneto.
00:31With Acto Triveneto we try to stand by these very fragile women.
00:37We help each other because we are all the same.
00:40Among the themes at the center of the Treviso stage of Cambiamo Rotta is the importance of genetic counseling.
00:46At the Caffoncello hospital in Treviso, since 2023,
00:49I have been working on a path for healthy people affected by genetic mutations BRCA1 and BRCA2
00:55that are detected through genetic testing.
00:58As for the treatment of ovarian cancer, today we can say that research helps a lot,
01:04that important drugs have arrived, such as parpinibutories.
01:09Thanks to the advent of these drugs, the BRCA test has been further enhanced,
01:15because before it was really a niche test.
01:18Before a test was done only for families, now enhanced by therapies.
01:22The initiative Cambiamo Rotta enjoys the unconditional support of GSK.
01:27It is important to be part of this path that really wants to contribute,
01:32to improve the quality of life and in general the management of women who today live with ovarian cancer.